Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication

Heavily treatment‐experienced patients with good virological control could be at risk of virological failure on switching to a new regimen if pre‐existing drug resistance is not taken into account. We examined whether genotyping based on cellular HIV‐1 DNA during controlled viraemia identifies resistance mutations detected in plasma HIV‐1 RNA during treatment with previous antiretroviral regimens.

[1]  V. Calvez,et al.  Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. , 2011, The Journal of antimicrobial chemotherapy.

[2]  O. Turriziani,et al.  Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  J. Yombi,et al.  HIV‐1 proviral resistance mutations: usefulness in clinical practice , 2010, HIV medicine.

[4]  Ingrid A. Beck,et al.  Detection of HIV-1 Drug Resistance in Women Following Administration of a Single Dose of Nevirapine: Comparison of Plasma RNA to Cellular DNA by Consensus Sequencing and by Oligonucleotide Ligation Assay , 2010, Journal of Clinical Microbiology.

[5]  D. Cooper,et al.  Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.

[6]  C. Delaugerre,et al.  Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  S. Buskin,et al.  Increased Detection of HIV-1 Drug Resistance at Time of Diagnosis by Testing Viral DNA With a Sensitive Assay , 2009, Journal of acquired immune deficiency syndromes.

[8]  L. Palmisano,et al.  The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy. , 2009, Journal of acquired immune deficiency syndromes.

[9]  R. Siliciano,et al.  Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. , 2009, The Journal of infectious diseases.

[10]  R. Diaz,et al.  Emergence of resistance mutations preceding virologic failure in patients receiving antiretroviral therapy. , 2008, Journal of Acquired Immune Deficiency Syndromes.

[11]  J. Izopet,et al.  HIV-1-Resistant Strains during 8-Week on 8-Week off Intermittent Therapy and their Effect on CD4+ T-cell Counts and Antiviral Response , 2008, Antiviral therapy.

[12]  Ariana Harari,et al.  Cytidine deamination induced HIV-1 drug resistance , 2008, Proceedings of the National Academy of Sciences.

[13]  D. Richman,et al.  Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.

[14]  E. Poveda,et al.  Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. , 2007, AIDS research and human retroviruses.

[15]  V. Calvez,et al.  Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey , 2007, AIDS.

[16]  S. Lagakos,et al.  Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.

[17]  C. Scagnolari,et al.  Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals , 2007, Journal of acquired immune deficiency syndromes.

[18]  V. Calvez,et al.  Repeated HIV‐1 resistance genotyping external quality assessments improve virology laboratory performance , 2006, Journal of medical virology.

[19]  C. Rouzioux,et al.  HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time , 2006, AIDS.

[20]  John W. Mellors,et al.  Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.

[21]  S. Hammer,et al.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. , 2004, The New England journal of medicine.

[22]  Yassine Taoufik,et al.  The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution , 2004, AIDS.

[23]  C. Verhofstede,et al.  Drug-Resistant Variants That Evolve During Nonsuppressive Therapy Persist in HIV-1–Infected Peripheral Blood Mononuclear Cells After Long-Term Highly Active Antiretroviral Therapy , 2004, Journal of acquired immune deficiency syndromes.

[24]  V. Calvez,et al.  Persistence of Multidrug-Resistant HIV-1 without Antiretroviral Treatment 2 Years after Sexual Transmission , 2003, Antiviral therapy.

[25]  S. Oka,et al.  Emergence of Protease Inhibitor Resistance–Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year , 2003, Journal of acquired immune deficiency syndromes.

[26]  J. Ragnaud,et al.  Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. , 2003, The Journal of infectious diseases.

[27]  Thomas C. Quinn,et al.  Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure , 2002, Journal of Virology.

[28]  M. Alvarez,et al.  Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. , 2002, The Journal of infectious diseases.

[29]  M. Mouroux,et al.  Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.

[30]  F. Baldanti,et al.  Analysis of HIV drug‐resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment‐naive and HAART patients , 2001, Journal of medical virology.

[31]  Jacques Izopet,et al.  Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.

[32]  N. Saksena,et al.  Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART , 2000, AIDS.

[33]  C. Sabin,et al.  Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. , 2000, AIDS research and human retroviruses.

[34]  C. Sabin,et al.  Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. , 2000, The Journal of infectious diseases.

[35]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.